American Association for Cancer Research
00085472can152786-sup-156561_1_supp_0_43f453.docx (61.34 kB)

Supplementary Methods and References from Quantitative Phosphotyrosine Profiling of Patient-Derived Xenografts Identifies Therapeutic Targets in Pediatric Leukemia

Download (61.34 kB)
journal contribution
posted on 2023-03-30, 23:53 authored by Sibasish Dolai, Keith C.S. Sia, Alissa K. Robbins, Ling Zhong, Sue L. Heatley, Tiffaney L. Vincent, Falko Hochgräfe, Rosemary Sutton, Raushan T. Kurmasheva, Tamas Revesz, Deborah L. White, Peter J. Houghton, Malcolm A. Smith, David T. Teachey, Roger J. Daly, Mark J. Raftery, Richard B. Lock

Description of additional methods and procedures used in the study. Also includes Supplementary References.


Australian National Health and Medical Research



Activating mutations in tyrosine kinases (TK) drive pediatric high-risk acute lymphoblastic leukemia (ALL) and confer resistance to standard chemotherapy. Therefore, there is urgent need to characterize dysregulated TK signaling axes in patients with ALL and identify actionable kinase targets for the development of therapeutic strategies. Here, we present the first study to quantitatively profile TK activity in xenografted patient biopsies of high-risk pediatric ALL. We integrated a quantitative phosphotyrosine profiling method with “spike-in” stable isotope labeling with amino acids in cell culture (SILAC) and quantified 1394 class I phosphorylation sites in 16 ALL xenografts. Moreover, hierarchical clustering of phosphotyrosine sites could accurately classify these leukemias into either B- or T-cell lineages with the high-risk early T-cell precursor (ETP) and Ph-like ALL clustering as a distinct group. Furthermore, we validated this approach by using specific kinase pathway inhibitors to perturb ABL1, FLT3, and JAK TK signaling in four xenografted patient samples. By quantitatively assessing the tyrosine phosphorylation status of activated kinases in xenograft models of ALL, we were able to identify and validate clinically relevant targets. Therefore, this study highlights the application and potential of phosphotyrosine profiling for identifying clinically relevant kinase targets in leukemia. Cancer Res; 76(9); 2766–77. ©2016 AACR.

Usage metrics

    Cancer Research



    Ref. manager